User login
Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).
Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P = .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P = .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P = .71).
Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.
Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2
Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).
Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P = .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P = .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P = .71).
Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.
Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2
Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).
Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P = .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P = .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P = .71).
Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.
Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2